Chemours (NYSE:CC) reported its Q1 earnings on Thursday, with EPS coming in at $0.98, better than the Street estimate of $0.54. Revenue was $1.6 billion, beating the Street estimate of $1.46 billion.
The company reaffirmed its 2023 EBITDA guidance of $1.2–1.3 billion, compared to the Street estimate of $1.24 billion. Adjusted EPS guidance is essentially unchanged at $3.78–4.28, compared to the prior guidance of $3.80-$4.29.
The company expects a weaker start to 2023, with conditions improving into the second half of the year, with continued secular growth in TSS and APM.